TENX — TENAX THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 34956 ·
Last close
$1.42
Market Cap
$64.66M
52W High
$19.40
52W Low
$1.31
ADV30
1,774,443
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -18,784,000 -17,803,000 121,663,000 117,976,000 8,073,000
Mar 2026 0 — -16,573,000 -15,716,000 123,178,000 118,755,000 8,486,000
Dec 2025 0 — -16,449,000 -15,540,000 104,227,000 97,565,000 7,156,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-46,029,000
Investing CF
$0
Financing CF
$58,543,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-400,973,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-66,701,000
Pretax Income TTM
$-64,863,000
Interest Exp TTM
$0
Analysts
7

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -56,385,000 -52,599,000 104,227,000 7,156,000 97,071,000 -35,800,000
Dec 2024 0 -19,494,000 -17,602,000 96,686,000 4,693,000 91,993,000 -14,811,000
Dec 2023 0 -8,234,000 -7,711,000 11,685,000 3,587,000 8,098,000 -5,904,000
Dec 2022 0 -11,052,643 -11,047,895 3,404,709 1,911,968 1,492,741 -11,388,571
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-64,863,000
OpCashFlow TTM
—
Assets (Latest)
$121,663,000
Forward EPS
$-1.50

Peers — same industry

TickerNameMarket CapLastDaily %
RANI Rani Therapeutics Holdings, Inc. $64.61M $0.56 —
KALA KALA BIO, Inc. $66.34M $3.43 —
CRBP Corbus Pharmaceuticals Holdings, Inc. $62.03M $3.01 —
GOSS Gossamer Bio, Inc. $67.52M $11.04 —
ACRV Acrivon Therapeutics, Inc. $61.28M $1.43 —

News headlines (Yahoo Finance, 1h cache)

Why Is Tencent Music Entertainment Stock Falling 3.1% in Pre-Market Trading?
2026-11-17 11:46 · Yahoo
Tenax Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:22 · Yahoo
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:00 · Yahoo
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
2026-09-04 22:26 · Yahoo
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
2026-09-01 11:00 · Yahoo
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
2026-08-29 12:21 · Yahoo
Tenax Therapeutics’ stock crashes on Phase III trial failure
2026-08-11 11:15 · Yahoo
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
2026-08-10 15:03 · Yahoo
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-31 11:00 · Yahoo
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.